+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Age: 18Years - 85Years
All Genders
ID06771011

Study Comparing RECAM and RUCAM Scores for Diagnosing Drug-Induced Liver Injury in Adults

Led by Beijing Friendship Hospital · Updated on 2025-01-13

407

Participants Needed

1

Research Sites

12 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are studying hospitalized patients with acute liver injury to compare two scoring systems, RECAM and RUCAM, for diagnosing drug-induced liver injury DILI. This observational study collects clinical, biochemical, imaging, and pathology data to evaluate the accuracy and consistency of these diagnostic tools. The study aims to understand whether RECAM performs as well as RUCAM in identifying DILI cases. Participants admitted between March 2023 and September 2024 will have their demographic information, clinical symptoms, lab results, imaging scans ultrasound, CT, MRI, and liver biopsy pathology reports collected. Three clinicians independently score each patient using RECAM and RUCAM to compare their diagnostic effectiveness and agreement. Statistical analyses will also explore relationships among clinical features, lab tests, imaging, and pathology. During the study, patients medical and diagnostic data will be thoroughly reviewed and scored by clinicians. The main outcome is to determine if RECAM is not inferior or inferior to RUCAM by July 2025. No treatments are given as this is an observational study. Participants will be monitored through their hospital stay and follow-up evaluations to confirm diagnoses and collect outcome information until the study ends in May 2026.

CONDITIONS

Brief Title

Prospective Comparative Validation Study of RUCAM and RECAM

Research Team

X

Xinyan Zhao

Y

Yao Meng

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here